Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05080140

Enrollment

Registered

2021-10-15

Start date

2019-06-01

Completion date

2022-03-20

Last updated

2021-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia; Mixed

Brief summary

This randomized controlled pharmacokinetic based study will be carried out on patients with both sexes and various ages, plasma triglycerides levels, clinical health disorders and using different agents for treatment of their hyperlipidemia in order to access the optimal drug therapy with best cost effectiveness in the elderly cases under investigation.

Interventions

DRUGEzetimibe 10mg

Effect of ezetimibe on hyperlipidemia on patients with diabetes mellites

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Patients of dyslipidemia with high triglyceride level (200 to 499 mg/100 ml). * Total cholesterol level more than 200 mg/100 ml * Male and female * Age 35 - 70 years

Exclusion criteria

* \- Hypersensitivity of drugs * Liver toxicity * -Patients suffering from renal dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Reduction of Total cholesterol	3 months	reduction of LDL

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026